A detailed history of State Of Wyoming transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, State Of Wyoming holds 48,016 shares of AKBA stock, worth $85,948. This represents 0.01% of its overall portfolio holdings.

Number of Shares
48,016
Previous 49,727 3.44%
Holding current value
$85,948
Previous $50,000 26.0%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.94 - $1.55 $1,608 - $2,652
-1,711 Reduced 3.44%
48,016 $63,000
Q2 2024

Aug 14, 2024

BUY
$0.86 - $1.63 $42,765 - $81,055
49,727 New
49,727 $50,000
Q4 2023

Feb 14, 2024

SELL
$0.8 - $1.28 $27,428 - $43,884
-34,285 Reduced 46.32%
39,725 $49,000
Q3 2023

Nov 14, 2023

BUY
$0.87 - $1.84 $22,448 - $47,477
25,803 Added 53.53%
74,010 $84,000
Q2 2023

Aug 14, 2023

BUY
$0.51 - $1.43 $24,585 - $68,936
48,207 New
48,207 $44,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $329M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track State Of Wyoming Portfolio

Follow State Of Wyoming and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.